Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges
Table 3
Clinicopathological factors associated with platelet count increase effect of avatrombopag.
Factors
Number (%)
Platelet count increase
value
Age (years)
≤55
46 (49.5)
42.0 (2.0∼287.0)
0.738
>55
47 (50.5)
41.0 (2.0∼322.0)
Gender
Male
68 (73.1)
40.0 (2.0∼287.0)
0.102
Female
25 (26.9)
45.0 (17.0∼322.0)
Etiology
HBV or HCV
72 (77.4)
41.0 (2.0∼287.0)
0.020
Nonviral
21 (22.6)
101.0 (23.0∼322.0)
Child-Pugh Grade
A
70 (75.3)
41.0 (2.0∼322.0)
0.682
B or C
23 (24.7)
42.0 (3.0∼284.0)
Combination with TPO or rhIL-11
Positive
30 (32.2)
69.0 (2.0∼287.0)
0.012
Negative
63 (67.7)
35.0 (2.0∼322.0)
Spleen volume index (cm3)
≤1000
41 (44.1)
54.0 (2.0∼322.0)
0.018
>1000
52 (55.9)
34.5 (2.0∼287.0)
Baseline platelet count (×109/L)
<40
37 (39.8)
42.0 (2.0∼322.0)
0.275
≥40
56 (60.2)
39.0 (2.0∼287.0)
ALBI score
≤−2.6
44 (47.3)
35.5 (2.0∼322.0)
0.131
>−2.6
49 (52.7)
45.0 (2.0∼287.0)
Values are median (range) and compared by the Mann-WhitneyU test; abbreviations: HBV: hepatitis B virus; HCV: hepatitis C virus; TPO: thrombopoietin; rhIL-11: recombinant human interleukin-11; P: positive; N: negative; ALBI score: albumin-bilirubin score.
